[Featured Stock] Paksel Bio Surges for Second Day on Anticancer Drug Approval Hopes

[Asia Economy Reporter Park Ji-hwan] The stock price of Baxel Bio is soaring day by day.

According to the Korea Exchange on the 25th, as of 9:16 a.m., Baxel Bio is trading at 138,100 KRW, up 15.18% from the previous trading day. Baxel Bio also closed at the upper limit the day before. This marks a continuous surge for the past three trading days including today.

It is interpreted that investor sentiment was stimulated as the government approval deadline for Baxlukin, an anticancer immunotherapy drug exclusively for companion dogs developed by Baxel Bio, is approaching. Baxel Bio is a company that researches and develops anticancer immunotherapy drugs.